Opthea Limited (OPT)
After hours:
| Previous Close | 3.6400 |
| Open | 3.5000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 3.4000 - 3.5000 |
| 52 Week Range | 1.6000 - 4.4200 |
| Volume | |
| Avg. Volume | 21,269 |
| Market Cap | 281.693M |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.22 |
GlobeNewswireOpthea to Present at the OIS Retina Innovation Summit at ARVO
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company’s clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina
Simply Wall St.Owning 39% shares,institutional owners seem interested in Opthea Limited (ASX:OPT),
Key Insights Institutions' substantial holdings in Opthea implies that they have significant influence over the...
- GlobeNewswire
Opthea Appoints John Han, PharmD, as VP Medical Affairs
Brings extensive experience in retinal and ophthalmology diseasesMELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective A
